Efferon CT Hemoadsorption for Cardiogenic Shock in Acute Myocardial Infarction (NCT06955936) | Clinical Trial Compass
RecruitingNot Applicable
Efferon CT Hemoadsorption for Cardiogenic Shock in Acute Myocardial Infarction
Russia60 participantsStarted 2025-04-29
Plain-language summary
Cardiogenic shock is the most severe manifestation of acute heart failure and remains the leading cause of death in patients hospitalised with acute myocardial infarction.
Cardiogenic shock is a well-known and potent trigger of the immune response, ischemia/reperfusion organ damage, hemolysis and release of free hemoglobin. The activation of immune cells leads to the release of cytokines and inflammatory mediators such as IL-6, IL-8, activated complement and others. As a result of myocardial ischaemia and reperfusion injury, a multiorgan dysfunction syndrome may develop.
The Efferon CT hemoadsorption device effectively removes cytokines and other pro-inflammatory molecules (≤55 kDa). This study evaluates whether this blood-filtering therapy can prevent organ failure in acute myocardial infarction patients with cardiogenic shock by eliminating inflammation-inducing mediators.
Who can participate
Age range
18 Years – 80 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Not more than 4 hours after diagnosis Cardiogenic shock complicating acute myocardial infarction
* Stages B - C of cardiogenic shock according to SCAI
* Patient condition allows treatment with Efferon® CT device for at least 4 hours
* SOFA score 12 or less
Exclusion Criteria:
* Broken-heart syndrome (takotsubo cardiomyopathy)
* Postcardiotomy cardiogenic shock
* Acute myocardial infarction within the last 4 weeks
* Myocarditis
* Cardiac trauma
* Charlson comorbidity index greater than 9 points
* Chronic kidney disease, stage 5 D (requiring continuous hemodialysis)
* Acute pulmonary embolism
* Acute cerebral circulatory collapse
* Transfusion reaction
* Patients on immunosuppressive therapy for cancer and autoimmune diseases
* Pregnancy
* Any other clinical condition of the patient that in the opinion of the investigator precludes inclusion in this study
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.